Arvinas reports Q3 2026 results, dosing starts in new HPK1 trial

Arvinas reported financial results for the third quarter of 2026 on November 3, 2026, alongside a corporate update covering its pipeline of protein-degrading PROTAC drugs.

The company said it had initiated dosing of patients in the monotherapy cohort of the Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT07749586) of ARV-6723, Arvinas' first immuno-oncology degrader.¹ That trial will evaluate ARV-6723 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.¹

For ARV-393, the BCL6 degrader being studied in non-Hodgkin lymphoma, Arvinas sent early-stage dose escalation results for review at the American Society of Hematology's December meeting. The company also continued dose escalation in the Phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT06393738) in patients with non-Hodgkin lymphoma (NHL).¹

For ARV-027, the polyQ-AR degrader for Kennedy's disease, Arvinas started dosing a new set of healthy volunteers at higher, repeated doses in its first-in-human Phase 1 study.

On ARV-102, the LRRK2 degrader for Parkinson's disease, new biomarker data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with changes in oculomotor function correlating with reductions in LRRK2 cerebrospinal fluid biomarkers and changes in synaptic biomarkers.¹ Arvinas said the U.S. investigational new drug application for this program stays paused, and the company's goal is to add U.S. trial sites once a planned Phase 1b study in progressive supranuclear palsy in the EU and UK wraps up.

On cash, the company reported cash, cash equivalents, restricted cash, and marketable securities of $558.9 million as of September 30, 2026, compared with $685.4 million as of December 31, 2025.¹ Arvinas said this position is sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028.¹